New Platform Detects MicroRNA Directly in Serum and Plasma
|
By LabMedica International staff writers Posted on 20 Oct 2015 |
Biotech and other life science researchers will benefit from the introduction of a novel microRNA (miRNA) detection platform.
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
The biotechnology company SomaGenics (Santa Cruz, CA, USA) has announced the launch of its novel miR-ID platform and assays for detecting miRNA using a circularization-based RT-qPCR method.
The miR-ID platform is highly sensitive, uses single-dye detection, and can discriminate miRNA isoforms with single nucleotide differences at any position along the molecule. The technology works well with all sample sources, including total RNA, cell lysates, and tissue lysates.
"The miR-ID miRNA detection platform is highly sensitive and provides much better sequence discrimination than leading competitors," said Brian Johnston, CEO of SomaGenics. "By using unmodified DNA primers, single-dye detection (SYBR green), and no specialized probes miR-ID helps keep costs low and allows for the rapid development of assays for miRNAs of interest."
In addition to applications with purified RNA samples, miR-ID has been incorporated into SomaGenics' miR-Direct technology for the direct quantification of microRNA from plasma or serum. miR-Direct utilizes solution-phase hybridization to capture probes, greatly improving the detection of low-abundance miRNAs over solid-state capture methods. This step allows concentration of target miRNAs and washing miRNAs to remove qPCR inhibitors, such as heparin, from plasma. By using a capture probe, miR-Direct eliminates the need for total RNA isolation, the most problematic and bias-prone step in currently available miRNA detection kits.
The miR-Direct/ID technology was introduced at the 11th Annual Meeting of the Oligonucleotide Therapeutics Society, which was held October 11-14, 2015, in Leiden, the Netherlands.
Related Links:
SomaGenics
MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.
The biotechnology company SomaGenics (Santa Cruz, CA, USA) has announced the launch of its novel miR-ID platform and assays for detecting miRNA using a circularization-based RT-qPCR method.
The miR-ID platform is highly sensitive, uses single-dye detection, and can discriminate miRNA isoforms with single nucleotide differences at any position along the molecule. The technology works well with all sample sources, including total RNA, cell lysates, and tissue lysates.
"The miR-ID miRNA detection platform is highly sensitive and provides much better sequence discrimination than leading competitors," said Brian Johnston, CEO of SomaGenics. "By using unmodified DNA primers, single-dye detection (SYBR green), and no specialized probes miR-ID helps keep costs low and allows for the rapid development of assays for miRNAs of interest."
In addition to applications with purified RNA samples, miR-ID has been incorporated into SomaGenics' miR-Direct technology for the direct quantification of microRNA from plasma or serum. miR-Direct utilizes solution-phase hybridization to capture probes, greatly improving the detection of low-abundance miRNAs over solid-state capture methods. This step allows concentration of target miRNAs and washing miRNAs to remove qPCR inhibitors, such as heparin, from plasma. By using a capture probe, miR-Direct eliminates the need for total RNA isolation, the most problematic and bias-prone step in currently available miRNA detection kits.
The miR-Direct/ID technology was introduced at the 11th Annual Meeting of the Oligonucleotide Therapeutics Society, which was held October 11-14, 2015, in Leiden, the Netherlands.
Related Links:
SomaGenics
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
New Serum Marker-Editing Strategy to Improve Diagnosis of Neurological Diseases
Tracking gene-expression changes in the brain is crucial for understanding neurological diseases, yet current monitoring tools are invasive or unable to capture subtle activity shifts over time.... Read more
World’s First Genetic Type 1 Diabetes Risk Test Enables Early Detection
Type 1 Diabetes (T1D) affects more than eight million people worldwide, with numbers expected to rise sharply. While most cases are genetically driven, only one in ten patients has a family history, making... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channelRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channelAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read more
AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
Complex digital biopsy images that typically take an expert pathologist up to 20 minutes to assess can now be analyzed in about one minute using a new artificial intelligence (AI) tool. The technology... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








